scholarly journals Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Enrique Redondo-Gonzalez ◽  
Leandro Nunes de Castro ◽  
Jesús Moreno-Sierra ◽  
María Luisa Maestro de las Casas ◽  
Vicente Vera-Gonzalez ◽  
...  
Keyword(s):  
Molecular Markers ◽  
Bladder Carcinoma ◽  
Clinical History ◽  
Prostatic Hyperplasia ◽  
Biological Behavior ◽  
Preoperative Imaging ◽  
Muscle Invasive ◽  
New Diagnosis

Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most common types of cancer in humans, killing thousands of people a year. This paper is based on the hypothesis that the use of clinical and histopathological data together with information about the concentration of various molecular markers in patients is useful for the prediction of outcomes and the design of treatments ofnonmuscle invasive bladder carcinoma(NMIBC). A population of 45 patients with a new diagnosis of NMIBC was selected. Patients withbenign prostatic hyperplasia(BPH),muscle invasive bladder carcinoma(MIBC),carcinoma in situ(CIS), and NMIBC recurrent tumors were not included due to their different clinical behavior. Clinical history was obtained by means of anamnesis and physical examination, and preoperative imaging and urine cytology were carried out for all patients. Then, patients underwent conventionaltransurethral resection(TURBT) and some proteomic analyses quantified the biomarkers (p53, neu, and EGFR). A postoperative follow-up was performed to detect relapse and progression. Clusterings were performed to find groups with clinical, molecular markers, histopathological prognostic factors, and statistics about recurrence, progression, and overall survival of patients with NMIBC. Four groups were found according to tumor sizes, risk of relapse or progression, and biological behavior. Outlier patients were also detected and categorized according to their clinical characters and biological behavior.

The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?

2020 ◽  
Author(s):  
Francesco Pierconti ◽  
Maurizio Martini ◽  
Vincenzo Fiorentino ◽  
Tonia Cenci ◽  
Sara Capodimonti ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Muscle Invasive

The relationship between ABO blood group type and tumor grade, stage, recurrence and progression in transitional cell carcinoma of the bladder: A preliminary report

2019 ◽  
Vol 13 (3) ◽  
pp. 205-209
Author(s):  
Deviprasad Tiwari ◽  
Harshit Garg ◽  
Brusabhanu Nayak ◽  
Prabhjot Singh ◽  
Amlesh Seth
Keyword(s):  
Bladder Cancer ◽  
Blood Group ◽  
Bladder Carcinoma ◽  
Statistical Significance ◽  
Transitional Cell ◽  
Abo Blood Group ◽  
Level Of Evidence ◽  
Muscle Invasive ◽  
Blood Grouping

Objectives: ABO blood grouping is a well-proven prognostic factor in many malignancies. This study aims to study the association and impact of ABO blood group on disease recurrence and progression in bladder carcinoma. Material and methods: Patients with bladder carcinoma undergoing transurethral resection of bladder tumor (TURBT) were studied prospectively for at least 1-year follow-up for recurrence and progression of the disease. Demographic profile along with blood group was noted. Results: Two hundred patients were included in the study and 194 patients were included in the final analysis. Muscle-invasive bladder cancer was present in 39 (20.1%) patients and the high-grade tumor was present in 88 (45.3%) patients. There was no statistical significance between the association of blood grouping and grade ( p=0.29) and stage of the disease ( p=0.20). During the follow-up period, there were 100 (64.5%) recurrences and 15 (9.7%) patients with non-muscle-invasive bladder carcinoma had progression. The association of blood group with recurrence ( p=0.66) and progression ( p=0.11) of disease was not statistically significant. Conclusion: There is no association between bladder cancer and ABO blood group in terms of grade and stage of the disease. The recurrence and progression of the disease did not differ significantly in different blood groups. Level of Evidence: 2b

scholarly journals Complication of treatment of carcinoma in situ of the bladder with photodynamic targeted cystodiathermy

2014 ◽  
Vol 96 (7) ◽  
pp. e30-e31
Author(s):  
K Murtagh ◽  
R Kockelbergh
Keyword(s):  
Radical Cystectomy ◽  
Blue Light ◽  
Treatment Option ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Disease Recurrence ◽  
Invasive Disease ◽  
Potential Complication ◽  
Muscle Invasive

We report two cases of bladder contracture following photodynamic or ‘blue light’ detection and cystodiathermy for bladder carcinoma in situ. These patients were unsuitable for treatment with immunotherapy/chemotherapy or had disease recurrence following such treatment. Radical cystectomy was not a treatment option in either patient. Each underwent serial photodynamic cystodiathermy over a three-year period. Neither patient developed muscle invasive disease. However, treatment resulted in contracture of the bladder and incontinence of urine. Patients need to be fully aware of this potential complication in order to make informed choices about their care.

Ability of urovysion FISH analysis to select patients with low- or intermediate-risk non-muscle-invasive bladder cancer (LI-NMIBC) for decreased surveillance.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 283-283
Author(s):  
H. M. Rosevear ◽  
A. J. Lightfoot ◽  
M. A. O'Donnell
Keyword(s):  
First Year ◽  
Fish Analysis ◽  
Low Grade ◽  
High Grade ◽  
Genetic Changes ◽  
Screening Intervals ◽  
Muscle Invasive ◽  
Initial Resection

283 Background: Recurrent LI-NMIBC is difficult to detect cytologically, requiring frequent cystoscopies. Urovysion's (Abbot Laboratories, Downers Grove, IL) fluorescent in situ hybridization assay (FISH) detects genetic changes associated with LI-NMIBC and may be useful in identifying patients for extended screening intervals. Methods: Charts of 54 consecutive patients with LI-NMIBC who underwent cystoscopy, cytology, and FISH analysis every 3 months for the first year after resection since 2004 were retrospectively identified and reviewed. We analyzed the number of tumors or high-grade cytologies that would have been missed if surveillance cystoscopy, cytology, and FISH analysis had not been done between 3 and 12 months post-resection for patients with a normal cystoscopy, cytology, and FISH analysis at 3 months after initial resection and compared those results to patients with normal cystoscopy, cytology, and abnormal FISH analysis. Results: Mean age of the 54 patients was 67 (range 25–89) and 41 were males. Thirty-nine patients had normal cystoscopy, cytology, and FISH analysis at 3-months follow-up. If no further surveillance was done until 1 year post-resection, 2 low-grade tumors (3 and 7 mm at 7 months post-resection) and 2 incidents of high-grade cytology would have been missed (4 of 39, 10%). Fifteen patients had normal cystoscopy and cytology but abnormal FISH analysis results at 3 months. If no further surveillance had been done until 1 year after resection, 6 tumors (6 of 15, 40%) (5, 8, 3, 3, 9, 2 mm at 5, 6, 6, 7, 9, 10 months post-resection) and no high-grade cytology would have been missed. Overall, statistically fewer patients with normal compared to abnormal FISH analysis at first follow-up developed tumors before 1 year (4 of 39 vs. 6 of 15, p=0.033). Conclusions: FISH analysis can be used to significantly increase our ability to select patients suitable for extended screening intervals. It may be prudent to include FISH analysis at the first post-resection follow-up before selecting patients with LI-NMIBC for an extended screening interval. [Table: see text]

Fate of disappeared hepatic metastasis after mFOLFOX6 plus bevacizumab therapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14127-e14127
Author(s):  
Hiroyuki Uetake ◽  
Toshiaki Ishikawa ◽  
Kenichi Sugihara
Keyword(s):  
Liver Metastasis ◽  
Liver Metastases ◽  
Complete Response ◽  
Preoperative Imaging ◽  
Current Topic ◽  
Resected Liver ◽  
Preoperative Ct ◽  
Limited Metastasis

e14127 Background: Neoadjuvant and conversion chemotherapy for liver limited metastasis from colorectal cancer (CRC) is a current topic. Minute liver metastasis sometimes disappears on preoperative imaging and intraoperative examination (including contrast enhanced intraoperative ultrasonography (CEIOUS)) after chemotherapy using highly effective regimen, such as FOLFOX or FOLFIRI with molecular targeted agent. We reported a high pathological complete response (CR) rate of resected liver metastasis from CRC after preoperative mFOLFOX6 plus bevacizumab (Bmab) therapy (AACR 2011, abstract #3218), but It is still unclear whether disappeared lesions after chemotherapy need to be removed. Methods: Out of 17 patients with liver limited metastasis from CRC treated with mFOLFOX6 plus Bmab therapy, 9 patients (52%) underwent liver resection after chemotherapy. In 6 of the 9 patients, one or more disappeared lesion(s) after the chemotherapy was not resected and followed up by enhanced CT once every 3 months. Follow up period was 9 to 33 months (22 months in median). Results: Before chemotherapy, 53 liver metastases were detected in the 6 patients. After chemotherapy, 29 (55%) lesions were not detected by preoperative CT or CEIOUS. All the 24 lesion, which were pointed out at the operation, were resected. By histological examination, no viable tumor cell was observed in 12 lesions (50%) among resected lesions. In follow up period, in situ recurrence occurred in 5 lesions (17%) in 4 patients. Three of the 4 patients underwent curative resection of re-detected liver metastases. Conclusions: It was reported that cancer cells remain over 80% of clinically disappeared lesion after conventional chemotherapy. In the present study, only 17% of disappeared lesion after mFOLFOX6 plus Bmab therapy caused in situ recurrence. With this result and a high pathological CR rate of the resected liver metastases after mFOLFOX6 plus Bmab therapy, it is speculated that complete resection for disappeared lesions after this chemotherapy is not always necessary.

Topical Epirubicin as Treatment of in Situ Bladder Carcinoma

1992 ◽  
Vol 59 (1) ◽  
pp. 83-85
Author(s):  
G. Pegoraro ◽  
C. Bondavalli ◽  
B. Dall'Oglio ◽  
L. Schiavon ◽  
M. Luciano ◽  
...  
Keyword(s):  
Complete Remission ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Urinary Cytology ◽  
Control Therapy ◽  
Grade 3

15 patients with primitive carcinoma in situ of the bladder were administered 50 mg/week of Epirubicin; 14 responded to this control therapy with negative urinary cytology and biopsies within an average of 25.6 months. After an average follow up of 47.7 months, 8 out of the 15 patients are still in a state of complete remission, 1 has a recurrent grade 3 carcinoma, 5 are in progression (3 T1 and 2 T2) and 1 has a grade 2 Ta recurrence. 3 patients died from the disease.

Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients

Cancer ◽  
1994 ◽  
Vol 74 (10) ◽  
pp. 2819-2827 ◽  
Author(s):  
Alan Pollack ◽  
Gunar K. Zagars ◽  
Colin P. Dinney ◽  
David A. Swanson ◽  
Andrew C. von Eschenbach
Keyword(s):  
Prognostic Factors ◽  
Bladder Carcinoma ◽  
Preoperative Radiotherapy ◽  
Long Term Follow Up ◽  
Muscle Invasive

Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up

1994 ◽  
Vol 26 (4) ◽  
pp. 437-442 ◽  
Author(s):  
R. Minervini ◽  
R. Felipetto ◽  
L. Vigano ◽  
M. Cecchi
Keyword(s):  
Mitomycin C ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Long Term Follow Up

Lobular Neoplasia: Is Surgical Excision Warranted?

2008 ◽  
Vol 74 (2) ◽  
pp. 172-177 ◽  
Author(s):  
Vance Y. Sohn ◽  
Zachary M. Arthurs ◽  
Flora S. Kim ◽  
Tommy A. Brown
Keyword(s):  
Breast Cancer ◽  
Lobular Carcinoma ◽  
Surgical Excision ◽  
Clinical History ◽  
Lobular Neoplasia ◽  
Surgical Biopsy ◽  
Atypical Lobular Hyperplasia ◽  
Open Surgical Biopsy

The treatment of breast cancer associated with lobular neoplasia detected on core needle biopsy (CNB) remains controversial. The purpose of this study was to review the prevalence of lobular neoplasia in CNB specimens and to correlate CNB pathology to final surgical pathology. Patients with lobular neoplasia were included for analysis in this retrospective review. Patients with concomitant malignant or atypical lesions were excluded. Method of initial diagnosis, clinical history, pathology results, and follow-up data were then analyzed. From January 1994 to December 2005, 5257 CNBs were performed at our tertiary level medical facility. Of patients with lobular neoplasia, 42 of 50 (84%) patients had atypical lobular hyperplasia, whereas 8 (16%) patients were diagnosed with lobular carcinoma in situ on CNB specimens. There were no associated malignancies in 21 patients who underwent immediate surgical excision. Of those patients who were serially followed, four developed malignancies at an average of 73 months after the sentinel diagnosis. Three of the four (75%) malignancies occurred in the ipsilateral breast. Patients with a diagnosis of lobular neoplasia by CNB should not routinely undergo an open surgical biopsy. Lobular neoplasia should only be considered a risk marker for future invasive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document